TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The BERN Ultrasound-enhanced Thrombolysis for Ilio-Femoral Deep Vein Thrombosis versUs Standard Catheter Directed thromboLysis Trial (BERNUTIFUL-Trial)
Brief Summary: Patients with deep vein thrombosis (DVT) of the ilio-femoral veins have increased risk for developing post-thrombotic syndrome (PTS) and recurrent venous thromboembolism compared to more distal DVT. There's evidence that the early removal of the obstructing thrombus by catheter directed thrombolysis (CDT) reduces the risk of developing a PTS, and a higher degree of thrombolysis is associated with lower incidence of PTS, better quality of life and lower risk of recurrent venous thromboembolism. A further development is ultrasound-enhanced thrombolysis combining CDT with a sophisticated catheter system that employs high-frequency, low-dose ultrasound. In vitro experiments showed that adding ultrasound to thrombolytic drugs accelerates thrombolysis while Ultrasound exposure alone results in no thrombolysis, however the superiority of ultrasound-enhanced thrombolysis over standard CDT has never been formally assessed in vivo. The hypothesis for this study is that ultrasound-enhanced thrombolysis reaches a higher degree of thrombolysis than standard CDT in patients with symptomatic ilio-femoral DVT.


Options:
A: Arm Label: Standard treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard treatment | Arm Label: Bivalirudin arm; Type: EXPERIMENTAL; Interventions: Drug: Bivalirudin Injection | Intervention Type: DRUG; Name: Bivalirudin Injection; Assigned to Arm(s): Bivalirudin arm | Intervention Type: DRUG; Name: Standard treatment; Assigned to Arm(s): Standard treatment
B: Arm Label: Doxycyclin and Rivaroxaban; Type: EXPERIMENTAL; Interventions: Drug: Doxycycline Tablets, Drug: Rivaroxaban 15Mg Tab | Arm Label: National Standard; Type: ACTIVE_COMPARATOR; Interventions: Combination Product: Hydroxychloroquine and Azithromycin | Intervention Type: DRUG; Name: Doxycycline Tablets; Assigned to Arm(s): Doxycyclin and Rivaroxaban | Intervention Type: DRUG; Name: Rivaroxaban 15Mg Tab; Assigned to Arm(s): Doxycyclin and Rivaroxaban | Intervention Type: COMBINATION_PRODUCT; Name: Hydroxychloroquine and Azithromycin; Assigned to Arm(s): National Standard
C: Arm Label: Therapeutic anticoagulation; Type: EXPERIMENTAL; Interventions: Drug: Enoxaparin | Arm Label: Prophylactic anticoagulation; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin | Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): Prophylactic anticoagulation, Therapeutic anticoagulation
D: Arm Label: CDT+US group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: CDT+US group | Arm Label: CDT-US group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: CDT-US group | Intervention Type: PROCEDURE; Name: CDT+US group; Assigned to Arm(s): CDT+US group | Intervention Type: PROCEDURE; Name: CDT-US group; Assigned to Arm(s): CDT-US group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Mild Cognitive Impairment and Obstructive Sleep Apnea
Brief Summary: Obstructive sleep apnea (OSA) has been linked to increased risk for Alzheimer's disease (AD), but little prospective evidence exists on the effects of OSA treatment in preclinical AD. The objective was to determine if CPAP treatment adherence, controlling for baseline differences, predicts cognitive and everyday function after 1 year in older adults with MCI and to determine effect sizes for a larger trial. The aim of the Mild Cognitive Impairment and Obstructive Sleep Apnea (Memories 1) trial was to determine whether CPAP treatment adherence, controlling for any baseline differences in OSA severity, ApoE4, and other previously identified demographic and patient factors, might predict cognitive and everyday function after 1 year in older adults with amnestic MCI.


Options:
A: Arm Label: Telemedecine; Type: EXPERIMENTAL; Interventions: Device: Telemedicine | Arm Label: Standard Care; Type: ACTIVE_COMPARATOR; Interventions: Device: Standard care | Intervention Type: DEVICE; Name: Telemedicine; Assigned to Arm(s): Telemedecine | Intervention Type: DEVICE; Name: Standard care; Assigned to Arm(s): Standard Care
B: Intervention Type: PROCEDURE; Name: continuous positive airway pressure; Assigned to Arm(s): N/A
C: Arm Label: CPAP First, MAD; Type: ACTIVE_COMPARATOR; Interventions: Device: CPAP, Device: MAD | Arm Label: MAD First, CPAP; Type: EXPERIMENTAL; Interventions: Device: CPAP, Device: MAD | Intervention Type: DEVICE; Name: CPAP; Assigned to Arm(s): CPAP First, MAD, MAD First, CPAP | Intervention Type: DEVICE; Name: MAD; Assigned to Arm(s): CPAP First, MAD, MAD First, CPAP
D: Arm Label: MCI/OSA/CPAP Adherent; Type: EXPERIMENTAL; Interventions: Behavioral: CPAP adherence intervention | Arm Label: MCI/OSA/CPAP Non-adherent; Type: EXPERIMENTAL; Interventions: Behavioral: Attention control intervention | Intervention Type: BEHAVIORAL; Name: CPAP adherence intervention; Assigned to Arm(s): MCI/OSA/CPAP Adherent | Intervention Type: BEHAVIORAL; Name: Attention control intervention; Assigned to Arm(s): MCI/OSA/CPAP Non-adherent

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective Randomized Open-labeled Trial Comparing RADIOEMBOLIZATION With Yttrium 90 Microspheres and Sorafenib in Patients With Advanced Hepatocellular Carcinoma
Brief Summary: The purpose of this study is to determine whether RADIOEMBOLIZATION with 90 Yttrium microspheres is more effective on overall survival in advanced Hepatocellular carcinoma (HCC) with or without portal venous obstruction and no extrahepatic extension than sorafenib which is now the standard treatment of advanced HCC.


Options:
A: Arm Label: sorafenib group; Type: ACTIVE_COMPARATOR; Interventions: Drug: sorafenib | Arm Label: radioembolization group; Type: ACTIVE_COMPARATOR; Interventions: Drug: SIR-Sphere | Intervention Type: DRUG; Name: sorafenib; Assigned to Arm(s): sorafenib group | Intervention Type: DRUG; Name: SIR-Sphere; Assigned to Arm(s): radioembolization group
B: Intervention Type: DEVICE; Name: Yttrium-90 microspheres (Therasphere MDS Nordion); Assigned to Arm(s): N/A
C: Arm Label: Sorafenib, Multikinase Inhibitor, Tablet; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sorafenib tosylate | Arm Label: SIR-Spheres, Microspheres, Device; Type: ACTIVE_COMPARATOR; Interventions: Device: SIR-Spheres | Intervention Type: DEVICE; Name: SIR-Spheres; Assigned to Arm(s): SIR-Spheres, Microspheres, Device | Intervention Type: DRUG; Name: Sorafenib tosylate; Assigned to Arm(s): Sorafenib, Multikinase Inhibitor, Tablet
D: Arm Label: Arm I (radioembolization); Type: EXPERIMENTAL; Interventions: Radiation: yttrium Y 90 glass microspheres | Arm Label: Arm II (transarterial chemoembolization [TACE]); Type: EXPERIMENTAL; Interventions: Drug: Doxorubicin | Intervention Type: RADIATION; Name: yttrium Y 90 glass microspheres; Assigned to Arm(s): Arm I (radioembolization) | Intervention Type: DRUG; Name: Doxorubicin; Assigned to Arm(s): Arm II (transarterial chemoembolization [TACE])

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Controlled Trial of Vertebroplasty for Acute Painful Osteoporotic Fractures.
Brief Summary: The objective of this study is to gather data regarding the efficacy, safety and cost-effectiveness of percutaneous vertebroplasty in the acute fracture group with fractures less than 6 weeks old. The AVAMAX vertebroplasty kits (Care Fusion) will be used for all vertebroplasties.

The primary effectiveness analysis will be based on the number of patients whose numeric rating pain score drops from above 7 out of 10 at baseline to below 4 out of 10 at two weeks post-intervention. Our hypothesis is that the vertebroplasty group will have a significantly larger proportion of patients achieving pain reduction than the control group. A secondary analysis will compare the change in mean pain scores and specific activity related pain scores between the two groups at 3 days, 14 days and at 1, 3 and 6 months. Another secondary effectiveness analysis will include the mean change in the back-pain specific limitation in function as quantified by the Roland Scale at these same data collection time points.


Options:
A: Arm Label: vertebroplasty; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Kyphoplasty | Arm Label: kyphoplasty; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Kyphoplasty | Intervention Type: PROCEDURE; Name: Kyphoplasty; Assigned to Arm(s): kyphoplasty, vertebroplasty
B: Arm Label: vertebroplasty; Type: ACTIVE_COMPARATOR; Interventions: Procedure: percutaneous injection of cement into the vertebral body | Arm Label: Medical Treatment; Type: ACTIVE_COMPARATOR; Interventions: Other: Medical treatment | Intervention Type: PROCEDURE; Name: percutaneous injection of cement into the vertebral body; Assigned to Arm(s): vertebroplasty | Intervention Type: OTHER; Name: Medical treatment; Assigned to Arm(s): Medical Treatment
C: Arm Label: AVAMAX; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Vertebroplasty | Arm Label: Simulated injection procedure; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Vertebroplasty; Assigned to Arm(s): AVAMAX
D: Arm Label: vertebroplasty; Type: EXPERIMENTAL; Interventions: Procedure: percutaneous vertebroplasty | Arm Label: sham procedure; Type: SHAM_COMPARATOR; Interventions: Procedure: sham procedure | Intervention Type: PROCEDURE; Name: percutaneous vertebroplasty; Assigned to Arm(s): vertebroplasty | Intervention Type: PROCEDURE; Name: sham procedure; Assigned to Arm(s): sham procedure

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Controlled Trial of Vertebroplasty for Acute Painful Osteoporotic Fractures.
Brief Summary: The objective of this study is to gather data regarding the efficacy, safety and cost-effectiveness of percutaneous vertebroplasty in the acute fracture group with fractures less than 6 weeks old. The AVAMAX vertebroplasty kits (Care Fusion) will be used for all vertebroplasties.

The primary effectiveness analysis will be based on the number of patients whose numeric rating pain score drops from above 7 out of 10 at baseline to below 4 out of 10 at two weeks post-intervention. Our hypothesis is that the vertebroplasty group will have a significantly larger proportion of patients achieving pain reduction than the control group. A secondary analysis will compare the change in mean pain scores and specific activity related pain scores between the two groups at 3 days, 14 days and at 1, 3 and 6 months. Another secondary effectiveness analysis will include the mean change in the back-pain specific limitation in function as quantified by the Roland Scale at these same data collection time points.


Options:
A: Arm Label: Vertebroplasty; Type: EXPERIMENTAL; Interventions: Device: Percutaneous vertebroplasty | Arm Label: Control Group; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Sham vertebroplasty | Intervention Type: DEVICE; Name: Percutaneous vertebroplasty; Assigned to Arm(s): Vertebroplasty | Intervention Type: PROCEDURE; Name: Sham vertebroplasty; Assigned to Arm(s): Control Group
B: Arm Label: vertebroplasty; Type: EXPERIMENTAL; Interventions: Procedure: percutaneous vertebroplasty | Arm Label: sham procedure; Type: SHAM_COMPARATOR; Interventions: Procedure: sham procedure | Intervention Type: PROCEDURE; Name: percutaneous vertebroplasty; Assigned to Arm(s): vertebroplasty | Intervention Type: PROCEDURE; Name: sham procedure; Assigned to Arm(s): sham procedure
C: Arm Label: AVAMAX; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Vertebroplasty | Arm Label: Simulated injection procedure; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Vertebroplasty; Assigned to Arm(s): AVAMAX
D: Arm Label: vertebroplasty; Type: ACTIVE_COMPARATOR; Interventions: Procedure: percutaneous injection of cement into the vertebral body | Arm Label: Medical Treatment; Type: ACTIVE_COMPARATOR; Interventions: Other: Medical treatment | Intervention Type: PROCEDURE; Name: percutaneous injection of cement into the vertebral body; Assigned to Arm(s): vertebroplasty | Intervention Type: OTHER; Name: Medical treatment; Assigned to Arm(s): Medical Treatment

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Online Treatments for Mood and Anxiety Disorders in Primary Care
Brief Summary: Depression and anxiety are common in primary care practice and are associated with substantial reductions in health-related quality of life. This Project will test the comparative effectiveness of two on-line treatments for these conditions provided through the context of a Collaborative Care program: (1) moderated access to a proven-effective computerized cognitive behavioral therapy (CCBT) program; versus (2) moderated access to CCBT plus an Internet support group (CCBT+ISG). The Project will also compare the effectiveness of these treatments to PCPs' "usual care" for these conditions, and evaluate the adoption and maintenance of CCBT+ISG by practices following the conclusion of the trial to provide a greater understanding of how to best scale the delivery of these interventions into a variety of primary care settings.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Nurse case management | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual care | Intervention Type: BEHAVIORAL; Name: Nurse case management; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Usual care; Assigned to Arm(s): 2
B: Arm Label: Computerized CBT + Internet Support Group; Type: EXPERIMENTAL; Interventions: Behavioral: CCBT+ISG/Collaborative Care | Arm Label: Computerized CBT Alone; Type: EXPERIMENTAL; Interventions: Behavioral: CCBT/Collaborative Care | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: CCBT+ISG/Collaborative Care; Assigned to Arm(s): Computerized CBT + Internet Support Group | Intervention Type: BEHAVIORAL; Name: CCBT/Collaborative Care; Assigned to Arm(s): Computerized CBT Alone
C: Arm Label: Chronic Care Model for Bipolar Disorder; Type: EXPERIMENTAL; Interventions: Behavioral: Chronic care model for Bipolar Disorder | Arm Label: Enhanced Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Chronic care model for Bipolar Disorder; Assigned to Arm(s): Chronic Care Model for Bipolar Disorder
D: Arm Label: Work rehab with cognitive therapy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Work rehabilitation based on the cognitive therapeutical model | Arm Label: Work rehab with cognitive training; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Work rehabilitation with the addition of cognitive training | Intervention Type: BEHAVIORAL; Name: Work rehabilitation based on the cognitive therapeutical model; Assigned to Arm(s): Work rehab with cognitive therapy | Intervention Type: BEHAVIORAL; Name: Work rehabilitation with the addition of cognitive training; Assigned to Arm(s): Work rehab with cognitive training

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase IIa, Randomised, Double-blind, Placebo-controlled, Parallel-arm, Multicenter Study to Evaluate the Efficacy and Safety of Tralokinumab (CAT-354), a Recombinant Human Monoclonal Antibody Directed Against Interleukin-13 (IL-13), as add-on Therapy, on Clinical Response in Patients With Active, Moderate-to-severe, Ulcerative Colitis
Brief Summary: The study is designed to evaluate the clinical efficacy and safety of tralokinumab as compared to placebo. Investigational product will be administered as subcutaneous injection. All patients will continue background therapy for ulcerative colitis as per local standards of care in addition to investigational product.


Options:
A: Arm Label: 1: budesonide-MMX® 6 mg; Type: EXPERIMENTAL; Interventions: Procedure: Blood sampling, endoscopy, Drug: Budesonide MMX® 6 mg | Arm Label: 2: budesonide-MMX® 9 mg; Type: EXPERIMENTAL; Interventions: Procedure: Blood sampling, endoscopy, Drug: Budesonide MMX® 9 mg | Arm Label: 3: Entocort EC® 3 mg; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Blood sampling, endoscopy, Drug: Entocort EC® 3 mg | Arm Label: 4: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Blood sampling, endoscopy, Drug: Placebo | Intervention Type: PROCEDURE; Name: Blood sampling, endoscopy; Assigned to Arm(s): 1: budesonide-MMX® 6 mg, 2: budesonide-MMX® 9 mg, 3: Entocort EC® 3 mg, 4: Placebo | Intervention Type: DRUG; Name: Budesonide MMX® 6 mg; Assigned to Arm(s): 1: budesonide-MMX® 6 mg | Intervention Type: DRUG; Name: Budesonide MMX® 9 mg; Assigned to Arm(s): 2: budesonide-MMX® 9 mg | Intervention Type: DRUG; Name: Entocort EC® 3 mg; Assigned to Arm(s): 3: Entocort EC® 3 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 4: Placebo
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: tralokinumab | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: tralokinumab; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2
C: Arm Label: 1 (i); Type: ACTIVE_COMPARATOR; Interventions: Drug: Rituximab | Arm Label: 2 (ii); Type: PLACEBO_COMPARATOR; Interventions: Drug: Rituximab | Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): 1 (i), 2 (ii)
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Golimumab 1 milligram (mg) per kilogram (kg); Type: EXPERIMENTAL; Interventions: Drug: Golimumab 1 mg per kg | Arm Label: Golimumab 2 mg per kg; Type: EXPERIMENTAL; Interventions: Drug: Golimumab 2 mg per kg | Arm Label: Golimumab 4 mg per kg; Type: EXPERIMENTAL; Interventions: Drug: Golimumab 4 mg per kg | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Golimumab 1 mg per kg; Assigned to Arm(s): Golimumab 1 milligram (mg) per kilogram (kg) | Intervention Type: DRUG; Name: Golimumab 2 mg per kg; Assigned to Arm(s): Golimumab 2 mg per kg | Intervention Type: DRUG; Name: Golimumab 4 mg per kg; Assigned to Arm(s): Golimumab 4 mg per kg

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Is Trauma-Focused Cognitive Behavioral Therapy Effective in Reducing Post-traumatic Stress and Psychosocial Distress Among Sexually Exploited, War-affected Girls in the Democratic Republic of Congo.
Brief Summary: To date, no RCT has examined the efficacy of Trauma-Focused Cognitive Behavioral Therapy with Sexually Exploited, War Affected Adolescent Girls in the Democratic Republic of Congo. This study seeks to fill this gap by designing, implementing and testing such an intervention using both an intervention and waiting list control group.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Risk Reduction through Family Therapy | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Risk Reduction through Family Therapy | Intervention Type: BEHAVIORAL; Name: Risk Reduction through Family Therapy; Assigned to Arm(s): 1, 2
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Prolonged Exposure for Adolescents | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Client Centered Therapy | Intervention Type: BEHAVIORAL; Name: Prolonged Exposure for Adolescents; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Client Centered Therapy; Assigned to Arm(s): 2
C: Arm Label: IPT arm; Type: EXPERIMENTAL; Interventions: Behavioral: interpersonal psychotherapy for groups | Arm Label: CP arm; Type: EXPERIMENTAL; Interventions: Behavioral: creative play therapy | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: interpersonal psychotherapy for groups; Assigned to Arm(s): IPT arm | Intervention Type: BEHAVIORAL; Name: creative play therapy; Assigned to Arm(s): CP arm
D: Arm Label: Trauma-Focused Cognitive Behavioral Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Trauma-Focused Cognitive Behavioral Therapy | Arm Label: Waiting List Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Trauma-Focused Cognitive Behavioral Therapy; Assigned to Arm(s): Trauma-Focused Cognitive Behavioral Therapy

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Is Trauma-Focused Cognitive Behavioral Therapy Effective in Reducing Post-traumatic Stress and Psychosocial Distress Among Sexually Exploited, War-affected Girls in the Democratic Republic of Congo.
Brief Summary: To date, no RCT has examined the efficacy of Trauma-Focused Cognitive Behavioral Therapy with Sexually Exploited, War Affected Adolescent Girls in the Democratic Republic of Congo. This study seeks to fill this gap by designing, implementing and testing such an intervention using both an intervention and waiting list control group.


Options:
A: Arm Label: Trauma-Focused Cognitive Behavioral Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Trauma-Focused Cognitive Behavioral Therapy | Arm Label: Waiting List Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Trauma-Focused Cognitive Behavioral Therapy; Assigned to Arm(s): Trauma-Focused Cognitive Behavioral Therapy
B: Arm Label: Control - VSLA; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Control - Mental Health; Type: OTHER; Interventions: Behavioral: Treatment as usual | Arm Label: Voluntary Savings/Loans Assoc; Type: EXPERIMENTAL; Interventions: Behavioral: Voluntary Savings/Loans Assoc | Arm Label: Cognitive Processing Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Processing Therapy | Intervention Type: BEHAVIORAL; Name: Treatment as usual; Assigned to Arm(s): Control - Mental Health | Intervention Type: BEHAVIORAL; Name: Voluntary Savings/Loans Assoc; Assigned to Arm(s): Voluntary Savings/Loans Assoc | Intervention Type: BEHAVIORAL; Name: Cognitive Processing Therapy; Assigned to Arm(s): Cognitive Processing Therapy
C: Arm Label: 1 Interpersonal Psychotherapy (IPT); Type: EXPERIMENTAL; Interventions: Behavioral: Interpersonal Psychotherapy | Arm Label: 2 Prolonged Exposure (PE); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Prolonged Exposure Therapy | Arm Label: 3 Relaxation therapy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Relaxation Therapy | Intervention Type: BEHAVIORAL; Name: Interpersonal Psychotherapy; Assigned to Arm(s): 1 Interpersonal Psychotherapy (IPT) | Intervention Type: BEHAVIORAL; Name: Prolonged Exposure Therapy; Assigned to Arm(s): 2 Prolonged Exposure (PE) | Intervention Type: BEHAVIORAL; Name: Relaxation Therapy; Assigned to Arm(s): 3 Relaxation therapy
D: Arm Label: IPT arm; Type: EXPERIMENTAL; Interventions: Behavioral: interpersonal psychotherapy for groups | Arm Label: CP arm; Type: EXPERIMENTAL; Interventions: Behavioral: creative play therapy | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: interpersonal psychotherapy for groups; Assigned to Arm(s): IPT arm | Intervention Type: BEHAVIORAL; Name: creative play therapy; Assigned to Arm(s): CP arm

Answer: A